SCHEMBL22378236

SCHEMBL22378236

N#Cc1ccc2c(c1)c1ccccc1n2-c1c(C#N)cccc1-c1cccc(-c2cccc(-n3c4ccccc4c4ccccc43)c2C#N)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
GABRA1 P14867 5/20 0.32
GABRG2 P18507 5/20 0.32
GABRB3 P28472 5/20 0.32
GABRA2 P47869 4/20 0.32
GABRA5 P31644 3/20 0.32
GABRA3 P34903 3/20 0.32
CYP19A1 P11511 1/20 0.32
ADRA2C P18825 1/20 0.32
HRH1 P35367 1/20 0.31
HTR6 P50406 1/20 0.31
PTGER4 P35408 1/20 0.30
RORC P51449 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22379138 0.95 SMN1; SMN2 (0.37) SMN1; SMN2HIF1APDCD1CD274HRH1
SCHEMBL22378298 0.95 SMN1; SMN2 (0.37) SMN1; SMN2HIF1APDCD1CD274HRH1
SCHEMBL22379032 0.94 SMN1; SMN2 (0.39) SMN1; SMN2HIF1APDCD1CD274GABRA1
SCHEMBL22378705 0.92 SMN1; SMN2 (0.44) SMN1; SMN2HIF1APDCD1CD274GABRA1
SCHEMBL22379758 0.90 SMN1; SMN2 (0.39) SMN1; SMN2HIF1APDCD1CD274GABRA1
SCHEMBL26613794 0.90 SMN1; SMN2 (0.39) SMN1; SMN2HIF1APDCD1CD274GABRA1
SCHEMBL22379069 0.90 SMN1; SMN2 (0.36) SMN1; SMN2HIF1AHRH1HTR6PTGER4
SCHEMBL22378034 0.90 SMN1; SMN2 (0.36) SMN1; SMN2HIF1AHRH1HTR6PTGER4
SCHEMBL26613896 0.90 PDCD1 (0.34) SMN1; SMN2HIF1APDCD1CD274ADRA2C
SCHEMBL22378032 0.89 PRKDC (0.33) GABRA1GABRG2GABRB3GABRA2GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-10-24 US disclosed
EP-3702349-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2023-01-04 EP disclosed
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200274074-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CYP1A1, CRY2 SMN1; SMN2 3839/4885HIF1A 844/4885PDCD1 1436/4885
US-11800797-B2 Heterocyclic compound and organic light-emitting device including the same CRY1, CYP1A1, CRY2 SMN1; SMN2 3839/4885HIF1A 844/4885PDCD1 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.